TerminatedPhase 3

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Stopped: The study was terminated early due to lack of efficacy from the primary analysis results.

United States775 participantsStarted 2021-11-05

Plain-language summary

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. BOTOX is being developed for the prevention of migraine in adults with episodic migraine (EM). Participants will be enrolled in 3 different treatment groups. There is 1 in 3 chance that participants will be assigned to receive placebo. Approximately 777 adult participants with EM will be enrolled in approximately 125 sites across the world. Participants will receive intramuscular injections (injected into the muscle) of BOTOX or Placebo on Day 1 and Week 12. Eligible participants will receive BOTOX on Week 24 and Week 36. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of migraine headache disorder meeting International Classification of Headache Disorders (ICHD)-3 diagnostic criteria for migraine with aura or migraine without aura for \>= 12 months. * Onset of migraine before 50 years of age. * History of 6 to 14 migraine days/month in each of the 3 months prior to Visit 1. * Six to 14 migraine/probable migraine days during the 4-week screening/baseline phase. * Less than 15 headache days/month in each of the 3 months prior to Visit 1 and during the 4-week screening/baseline phase. Exclusion Criteria: * Current diagnosis of chronic migraine according to ICHD-3. * History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, chronic tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua, or new daily persistent headache. * History of headache attributed to another disorder (e.g., cervical dystonia, craniotomy, head/neck trauma) with exception that medication overuse headache per ICHD-3 criteria is allowed. * History of inadequate response to \> 4 prophylactic treatment for migraine, 2 of which have different mechanisms of action. * Female who is pregnant, breastfeeding, or considering becoming pregnant during the study or within 90 days after the last dose of study drug.

What they're measuring

Change From Baseline in the Frequency of Monthly Migraine Days Across Months 5 and 6

Timeframe: Baseline, Months 5-6

Number of Participants With Treatment-Emergent Adverse Events (AEs)

Timeframe: Double-Blind Phase (Week 0-24); Open-Label Phase (Week 24-48)

Trial details

NCT IDNCT05028569

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-11-06

Results submitted2025-10-31